立体定向放射外科治疗颅内血管外皮细胞瘤:荟萃分析综述。

IF 1.5 4区 医学 Q3 CLINICAL NEUROLOGY
João Vitor Andrade Fernandes, Maria Antonia Oliveira Machado Pereira, Ocílio Ribeiro Gonçalves, Paweł Łajczak, Rafael Reis de Oliveira, Luana Miyahira Makita, Maurus Marques de Almeida Holanda
{"title":"立体定向放射外科治疗颅内血管外皮细胞瘤:荟萃分析综述。","authors":"João Vitor Andrade Fernandes, Maria Antonia Oliveira Machado Pereira, Ocílio Ribeiro Gonçalves, Paweł Łajczak, Rafael Reis de Oliveira, Luana Miyahira Makita, Maurus Marques de Almeida Holanda","doi":"10.1080/01616412.2025.2553861","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Intracranial hemangiopericytomas (HPCs) are rare and aggressive mesenchymal tumors with high rates of local recurrence and metastasis. This meta-analysis evaluates the effectiveness of stereotactic radiosurgery (SRS) in managing these tumors.</p><p><strong>Methods: </strong>A systematic search was conducted up to January 2025 for studies reporting outcomes of SRS in intracranial HPCs. Inclusion criteria comprised original studies with extractable data on at least one predefined outcome. Data were synthesized using random-effects meta-analysis, with heterogeneity assessed by I<sup>2</sup> statistics. Sensitivity analyses and influence diagnostics were performed. Risk of bias was evaluated using ROBINS-I, and publication bias was assessed with funnel plots and Egger's test when applicable.</p><p><strong>Results: </strong>Sixteen studies (329 patients, 483 tumors) were included. Tumor size reduction occurred in 47.9% (95% CI: 36.1-59.7%; I<sup>2</sup> = 81%) and complete response in 29.9% (95% CI: 16.5-43.3%; I<sup>2</sup> = 74%). Tumor progression was reported in 22.7% (95% CI: 9.1-36.4%; I<sup>2</sup> = 90%) and tumor stability in 12.1% (95% CI: 6.2-17.9%; I<sup>2</sup> = 63%). Extracranial metastases occurred in 21.3% of patients (95% CI: 16.1-26.5%; I<sup>2</sup> = 0%). Neurological improvement was observed in 16.0% (95% CI: 9.2-22.8%; I<sup>2</sup> = 28%), and mortality reached 31.3% (95% CI: 20.7-41.8%; I<sup>2</sup> = 71%). Treatment-related complications occurred in 10.8% (95% CI: 2.5-19.2%; I<sup>2</sup> = 0%). No major publication bias was identified.</p><p><strong>Conclusion: </strong>SRS provides meaningful tumor control and favorable safety in intracranial HPCs, with notable rates of size reduction and complete response, though progression, metastasis, and mortality remain substantial.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1-14"},"PeriodicalIF":1.5000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Stereotactic radiosurgery in the management of intracranial hemangiopericytomas: a meta-analytic review.\",\"authors\":\"João Vitor Andrade Fernandes, Maria Antonia Oliveira Machado Pereira, Ocílio Ribeiro Gonçalves, Paweł Łajczak, Rafael Reis de Oliveira, Luana Miyahira Makita, Maurus Marques de Almeida Holanda\",\"doi\":\"10.1080/01616412.2025.2553861\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Intracranial hemangiopericytomas (HPCs) are rare and aggressive mesenchymal tumors with high rates of local recurrence and metastasis. This meta-analysis evaluates the effectiveness of stereotactic radiosurgery (SRS) in managing these tumors.</p><p><strong>Methods: </strong>A systematic search was conducted up to January 2025 for studies reporting outcomes of SRS in intracranial HPCs. Inclusion criteria comprised original studies with extractable data on at least one predefined outcome. Data were synthesized using random-effects meta-analysis, with heterogeneity assessed by I<sup>2</sup> statistics. Sensitivity analyses and influence diagnostics were performed. Risk of bias was evaluated using ROBINS-I, and publication bias was assessed with funnel plots and Egger's test when applicable.</p><p><strong>Results: </strong>Sixteen studies (329 patients, 483 tumors) were included. Tumor size reduction occurred in 47.9% (95% CI: 36.1-59.7%; I<sup>2</sup> = 81%) and complete response in 29.9% (95% CI: 16.5-43.3%; I<sup>2</sup> = 74%). Tumor progression was reported in 22.7% (95% CI: 9.1-36.4%; I<sup>2</sup> = 90%) and tumor stability in 12.1% (95% CI: 6.2-17.9%; I<sup>2</sup> = 63%). Extracranial metastases occurred in 21.3% of patients (95% CI: 16.1-26.5%; I<sup>2</sup> = 0%). Neurological improvement was observed in 16.0% (95% CI: 9.2-22.8%; I<sup>2</sup> = 28%), and mortality reached 31.3% (95% CI: 20.7-41.8%; I<sup>2</sup> = 71%). Treatment-related complications occurred in 10.8% (95% CI: 2.5-19.2%; I<sup>2</sup> = 0%). No major publication bias was identified.</p><p><strong>Conclusion: </strong>SRS provides meaningful tumor control and favorable safety in intracranial HPCs, with notable rates of size reduction and complete response, though progression, metastasis, and mortality remain substantial.</p>\",\"PeriodicalId\":19131,\"journal\":{\"name\":\"Neurological Research\",\"volume\":\" \",\"pages\":\"1-14\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurological Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/01616412.2025.2553861\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/01616412.2025.2553861","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

颅内血管外皮细胞瘤是一种罕见的侵袭性间充质肿瘤,具有较高的局部复发和转移率。本荟萃分析评估了立体定向放射外科(SRS)治疗这些肿瘤的有效性。方法:系统检索截至2025年1月报道颅内HPCs患者SRS结果的研究。纳入标准包括具有至少一个预定义结果的可提取数据的原始研究。采用随机效应荟萃分析综合数据,采用I2统计量评估异质性。进行敏感性分析和影响诊断。偏倚风险评价采用ROBINS-I,发表偏倚评价采用漏斗图和Egger检验(如适用)。结果:纳入16项研究(329例患者,483例肿瘤)。肿瘤缩小率为47.9% (95% CI: 36.1-59.7%; I2 = 81%),完全缓解率为29.9% (95% CI: 16.5-43.3%; I2 = 74%)。肿瘤进展占22.7% (95% CI: 9.1-36.4%; I2 = 90%),肿瘤稳定占12.1% (95% CI: 6.2-17.9%; I2 = 63%)。21.3%的患者发生颅外转移(95% CI: 16.1-26.5%; I2 = 0%)。神经系统改善率为16.0% (95% CI: 9.2-22.8%; I2 = 28%),死亡率为31.3% (95% CI: 20.7-41.8%; I2 = 71%)。治疗相关并发症发生率为10.8% (95% CI: 2.5-19.2%; I2 = 0%)。未发现重大发表偏倚。结论:SRS在颅内HPCs中提供了有意义的肿瘤控制和良好的安全性,尽管进展、转移和死亡率仍然很高,但其体积缩小率和完全缓解率显著。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Stereotactic radiosurgery in the management of intracranial hemangiopericytomas: a meta-analytic review.

Introduction: Intracranial hemangiopericytomas (HPCs) are rare and aggressive mesenchymal tumors with high rates of local recurrence and metastasis. This meta-analysis evaluates the effectiveness of stereotactic radiosurgery (SRS) in managing these tumors.

Methods: A systematic search was conducted up to January 2025 for studies reporting outcomes of SRS in intracranial HPCs. Inclusion criteria comprised original studies with extractable data on at least one predefined outcome. Data were synthesized using random-effects meta-analysis, with heterogeneity assessed by I2 statistics. Sensitivity analyses and influence diagnostics were performed. Risk of bias was evaluated using ROBINS-I, and publication bias was assessed with funnel plots and Egger's test when applicable.

Results: Sixteen studies (329 patients, 483 tumors) were included. Tumor size reduction occurred in 47.9% (95% CI: 36.1-59.7%; I2 = 81%) and complete response in 29.9% (95% CI: 16.5-43.3%; I2 = 74%). Tumor progression was reported in 22.7% (95% CI: 9.1-36.4%; I2 = 90%) and tumor stability in 12.1% (95% CI: 6.2-17.9%; I2 = 63%). Extracranial metastases occurred in 21.3% of patients (95% CI: 16.1-26.5%; I2 = 0%). Neurological improvement was observed in 16.0% (95% CI: 9.2-22.8%; I2 = 28%), and mortality reached 31.3% (95% CI: 20.7-41.8%; I2 = 71%). Treatment-related complications occurred in 10.8% (95% CI: 2.5-19.2%; I2 = 0%). No major publication bias was identified.

Conclusion: SRS provides meaningful tumor control and favorable safety in intracranial HPCs, with notable rates of size reduction and complete response, though progression, metastasis, and mortality remain substantial.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neurological Research
Neurological Research 医学-临床神经学
CiteScore
3.60
自引率
0.00%
发文量
116
审稿时长
5.3 months
期刊介绍: Neurological Research is an international, peer-reviewed journal for reporting both basic and clinical research in the fields of neurosurgery, neurology, neuroengineering and neurosciences. It provides a medium for those who recognize the wider implications of their work and who wish to be informed of the relevant experience of others in related and more distant fields. The scope of the journal includes: •Stem cell applications •Molecular neuroscience •Neuropharmacology •Neuroradiology •Neurochemistry •Biomathematical models •Endovascular neurosurgery •Innovation in neurosurgery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信